Simvastatin Tablets Recalled Due to Manufacturing Practice Deviations
Accord Healthcare is recalling Simvastatin 20 mg tablets due to manufacturing practice deviations discovered during an FDA inspection. The recall affects 1,394,208 bottles distributed in the United States, Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II recall due to manufacturing process deviations discovered during FDA inspection. No illnesses or injuries have been reported. As the specific hazard resulting from these deviations is not identified in the source, this is scored as a precautionary manufacturing-related recall.
Plain-English summary
Accord Healthcare is recalling Simvastatin 20 mg tablets manufactured by Intas Pharmaceuticals Limited due to manufacturing practice deviations discovered during an FDA inspection.
The recall includes 1,394,208 bottles distributed across the United States, Puerto Rico, and Canada. Affected products include both 90-count and 1,000-count bottles with multiple batch numbers and expiration dates ranging from March 2023 through May 2025.
The FDA identified Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility. These deviations indicate non-compliance with manufacturing standards designed to ensure drug quality and safety.
Patients should consult their healthcare provider regarding their Simvastatin prescription, particularly if they have taken medication from an affected batch. For information about specific batch numbers and further details, consumers can visit the FDA's drug recalls website or contact Accord Healthcare directly.
The recalled product
- Product
- SIMVASTATIN (SIMVASTATIN)
- Brand
- SIMVASTATIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Prescription Drug
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2102261
- P2102284
- P2102319
- Exp. Date 3/31/2023
- P2103536
- Exp. Date 5/31/2023
- P2104344
- P2104342
- P2104355
- P2104356
- P2104296
- P2104380
- Exp. Date 6/30/2023
- R2200238
- R2200239
- Exp. Date 1/31/2024
- R2200383
- Exp. Date 2/28/2025
- b) R2000554
- R2000553
UPCs (2)
- 316729005159
- 316729005173
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · SIMVASTATIN
- HighSimvastatin 40 mg tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighPrescription Drug Simvastatin Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- HighAccord Healthcare Simvastatin 80 mg Tablets Recalled for Manufacturing Practice Violations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27